AR095658A1 - Método para la predicción de los síntomas extrapiramidales (sep) inducidos por un tratamiento basado en antipsicóticos - Google Patents
Método para la predicción de los síntomas extrapiramidales (sep) inducidos por un tratamiento basado en antipsicóticosInfo
- Publication number
- AR095658A1 AR095658A1 ARP140100210A ARP140100210A AR095658A1 AR 095658 A1 AR095658 A1 AR 095658A1 AR P140100210 A ARP140100210 A AR P140100210A AR P140100210 A ARP140100210 A AR P140100210A AR 095658 A1 AR095658 A1 AR 095658A1
- Authority
- AR
- Argentina
- Prior art keywords
- sep
- induced
- antipsychotic
- symptoms
- predicting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente incluye métodos para predicción de la aparición de síntomas extrapiramidales (SEP) inducidos por un tratamiento basado en antipsicóticos, así como métodos para proporcionar una medicina personalizada a los pacientes en base a la secuencia de varios SNPs asociados con la aparición de SEP. Se contempla también kits para llevar a cabo los métodos diagnósticos y predictivos. Reivindicación 1: Método para predecir la aparición de síntomas extrapiramidales (SEP) inducidos por un tratamiento basado en antipsicóticos en un sujeto, que comprende i) determinar la secuencia de los polimorfismos de un solo nucleótido (SNP) rs1130214, rs456998, rs7211818 y rs1053639 en una muestra que comprenda material genético de dicho sujeto, y ii) predecir el riesgo de dicho sujeto de desarrollar SEP en base a la secuencia de dichos SNPs.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13382027 | 2013-01-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR095658A1 true AR095658A1 (es) | 2015-11-04 |
Family
ID=47681823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140100210A AR095658A1 (es) | 2013-01-25 | 2014-01-24 | Método para la predicción de los síntomas extrapiramidales (sep) inducidos por un tratamiento basado en antipsicóticos |
Country Status (12)
Country | Link |
---|---|
US (2) | US9822415B2 (es) |
EP (1) | EP2948563B1 (es) |
JP (2) | JP6695142B2 (es) |
KR (1) | KR102033813B1 (es) |
CN (1) | CN104937113B (es) |
AR (1) | AR095658A1 (es) |
BR (1) | BR112015017815B1 (es) |
CA (1) | CA2898414C (es) |
ES (1) | ES2764154T3 (es) |
IL (1) | IL240129B (es) |
MX (1) | MX371426B (es) |
WO (1) | WO2014114734A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2898414C (en) | 2013-01-25 | 2021-11-02 | Centro De Investigacion Biomedica En Red (Ciber) | Method for predicting the onset of extrapyramidal symptoms (eps) induced by an antipsychotic-based treatment |
AU2017261283B2 (en) * | 2016-05-04 | 2023-02-09 | Children's Hospital & Research Center At Oakland | Rapid extraction of nucleic acids from clinical samples for downstream applications |
WO2018202740A1 (en) * | 2017-05-04 | 2018-11-08 | Universitat De Barcelona | Method for predicting early onset and severity of levodopa induced dyskinesia (lid) in subjects diagnosed of parkinson disease (pd) |
JP6935079B2 (ja) * | 2017-05-09 | 2021-09-15 | 国立大学法人千葉大学 | 機能的snpの組合せ解析 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090104598A1 (en) * | 2006-04-20 | 2009-04-23 | Centre For Addiction And Mental Health | Dopamine D2 receptor gene variants |
ATE523602T1 (de) * | 2006-06-12 | 2011-09-15 | Hadasit Med Res Service | Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen |
US20080206768A1 (en) * | 2006-12-18 | 2008-08-28 | Maria Arranz | Predicting a response to olanzapine |
WO2009089120A2 (en) * | 2008-01-02 | 2009-07-16 | Suregene Llc | Genetic markers of mental illness |
CA2712075A1 (en) * | 2008-01-17 | 2009-07-23 | Suregene Llc | Genetic markers of mental illness |
KR101653707B1 (ko) | 2008-05-29 | 2016-09-02 | 알바니 몰레큘라 리써치, 인크. | 5-ht3 수용체 조절제, 이의 제조 방법, 및 그의 용도 |
EP2344672B8 (en) * | 2008-09-25 | 2014-12-24 | SureGene LLC | Genetic markers for optimizing treatment for schizophrenia |
US7972793B2 (en) * | 2009-11-04 | 2011-07-05 | Suregene, Llc | Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype |
US20110223597A1 (en) * | 2010-03-10 | 2011-09-15 | The Penn State Research Foundation | Methods relating to olanzapine pharmacogenetics |
WO2011148379A2 (en) * | 2010-05-27 | 2011-12-01 | Hadasit Medical Research Services And Development Ltd. | Antipsychotic-induced parkinsonism genotypes and methods of using same |
TWI535535B (zh) | 2012-07-06 | 2016-06-01 | 聖高拜磨料有限公司 | 用於低速研磨操作之磨料物品 |
CA2898414C (en) * | 2013-01-25 | 2021-11-02 | Centro De Investigacion Biomedica En Red (Ciber) | Method for predicting the onset of extrapyramidal symptoms (eps) induced by an antipsychotic-based treatment |
-
2014
- 2014-01-24 CA CA2898414A patent/CA2898414C/en active Active
- 2014-01-24 AR ARP140100210A patent/AR095658A1/es unknown
- 2014-01-24 WO PCT/EP2014/051369 patent/WO2014114734A1/en active Application Filing
- 2014-01-24 US US14/763,292 patent/US9822415B2/en active Active
- 2014-01-24 KR KR1020157022967A patent/KR102033813B1/ko active IP Right Grant
- 2014-01-24 EP EP14701206.6A patent/EP2948563B1/en active Active
- 2014-01-24 BR BR112015017815-4A patent/BR112015017815B1/pt active IP Right Grant
- 2014-01-24 CN CN201480005929.1A patent/CN104937113B/zh active Active
- 2014-01-24 JP JP2015554151A patent/JP6695142B2/ja active Active
- 2014-01-24 MX MX2015009726A patent/MX371426B/es active IP Right Grant
- 2014-01-24 ES ES14701206T patent/ES2764154T3/es active Active
-
2015
- 2015-07-23 IL IL240129A patent/IL240129B/en active IP Right Grant
-
2017
- 2017-11-17 US US15/815,967 patent/US10954563B2/en active Active
-
2020
- 2020-01-06 JP JP2020000418A patent/JP2020089370A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
IL240129A0 (en) | 2015-09-24 |
BR112015017815B1 (pt) | 2022-06-14 |
WO2014114734A1 (en) | 2014-07-31 |
US10954563B2 (en) | 2021-03-23 |
IL240129B (en) | 2020-01-30 |
US20150354005A1 (en) | 2015-12-10 |
JP2016512950A (ja) | 2016-05-12 |
JP2020089370A (ja) | 2020-06-11 |
MX2015009726A (es) | 2015-11-06 |
ES2764154T3 (es) | 2020-06-02 |
KR20150107885A (ko) | 2015-09-23 |
EP2948563B1 (en) | 2019-10-02 |
BR112015017815A2 (pt) | 2017-11-21 |
CN104937113B (zh) | 2021-07-30 |
US9822415B2 (en) | 2017-11-21 |
CN104937113A (zh) | 2015-09-23 |
JP6695142B2 (ja) | 2020-05-20 |
CA2898414A1 (en) | 2014-07-31 |
MX371426B (es) | 2020-01-24 |
CA2898414C (en) | 2021-11-02 |
US20180230541A1 (en) | 2018-08-16 |
EP2948563A1 (en) | 2015-12-02 |
KR102033813B1 (ko) | 2019-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020010947A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
AR077026A1 (es) | Marcadores de riesgo para enfermedades cardiovasculares | |
CR9315A (es) | Metodos y sistemas para el diagnostico, pronostico y seleccion del tratamiento de la leucemia | |
AR088827A1 (es) | Metodos para tratar, diagnosticar, y monitorear la enfermedad de alzheimer | |
AR095658A1 (es) | Método para la predicción de los síntomas extrapiramidales (sep) inducidos por un tratamiento basado en antipsicóticos | |
MX2016002529A (es) | Marcadores de riesgo para cardiovasculopatias en pacientes con nefropatia cronica. | |
ES2524164B1 (es) | Pronóstico de respuesta al tratamiento con anti-tnfalfa en pacientes de artritis reumatoide | |
RU2012123226A (ru) | Способ прогнозирования риска развития стрессового перелома костей нижних конечностей | |
UA108659U (uk) | Спосіб діагностики розвитку остеопорозу | |
UA109397U (uk) | Спосіб діагностики розвитку остеопорозу | |
UA95639U (uk) | Спосіб прогнозування зрощення перелому | |
UA95644U (uk) | Спосіб прогнозування зрощення перелому | |
UA95641U (uk) | Спосіб прогнозування зрощення перелому | |
UA108278U (uk) | Спосіб прогнозування розвитку остеопорозу | |
UA113361U (uk) | Спосіб діагностики розвитку остеопорозу | |
UA96670U (uk) | Спосіб прогнозування зрощення перелому | |
UA111397U (uk) | Спосіб діагностики розвитку остеопорозу | |
UA111740U (uk) | Спосіб діагностики розвитку остеопорозу | |
UA96990U (uk) | Спосіб прогнозування зрощення перелому | |
UA95657U (uk) | Спосіб прогнозування зрощення перелому | |
UA97858U (uk) | Спосіб прогнозування зрощення перелому | |
UA108279U (uk) | Спосіб прогнозування розвитку остеопорозу | |
UA95642U (uk) | Спосіб прогнозування зрощення перелому | |
UA109472U (uk) | Спосіб діагностики розвитку остеопорозу | |
UA109274U (uk) | Спосіб прогнозування розвитку остеопорозу |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |